Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

AbbVie’s model fair value is held at US$253.55 per share, signaling no change to the core price target after factoring in the proposed Apogee Therapeutics acquisition. Research around the US$10.9b deal points to a split view, with some analysts highlighting the immunology and atopic dermatitis opportunity, while others question how much value the company can capture against rising competition. As you read on, you will see how these mixed signals are shaping the evolving AbbVie story and what to watch as the narrative develops.

Stay updated as the Fair Value for AbbVie shifts by adding it to your watchlist or Source link